The 2021 Fierce Pharma Marketing Awards To view this email as a web page,
click here Providers cry foul over new surprise billing rule's arbitration process Researchers retract preprint study that miscalculated higher heart inflammation risk for Moderna, Pfizer COVID vaccines The 2021 Fierce Pharma Marketing Awards MoonLake over the moon with $230M SPAC deal for llama antibodies to challenge Novartis' Cosentyx FDA greenlights combination at-home test for COVID and influenza in children as flu season approaches New insights into the ‘second brain’ in the gut could inspire treatments for intestinal diseases MSU team reports Humana launching 72 new Medicare plans for 2022 UCSF's customized 'pacemaker for the brain' successfully treats severe depression Anatara partners with virtual trials company ObvioHealth for siteless IBS study in Australia Roche, Takeda and Pfizer notch top scores among rare disease patient advocacy groups Featured Story | By Robert King Providers are united in opposition to the Biden administration's latest surprise billing rule, claiming it tilts a dispute resolution process in payers' favor. read more |
| |
|---|
|
Top Stories By Angus Liu In the past few weeks, anti-vaxxers have rallied behind a nonpeer-reviewed study by a group of Canadian researchers as evidence against COVID-19 vaccines. Turns out, the paper made a fatal mistake in reaching its conclusion. read more By Beth Snyder Bulik After a year when it seems like creativity should have hit a pause, the Fierce Pharma Marketing Award winners are proof of just the opposite. read more By Kyle LaHucik Just five months after debuting with a nanobody licensed from Merck KGaA, MoonLake Immunotherapeutics is headed to Wall Street. The Swiss biotech is linking arms with blank-check company Helix Acquisition in a SPAC deal that will give MoonLake $230 million in proceeds. read more By Conor Hale Labcorp aims to tackle both infections with a single test, with an at-home collection kit for gathering samples from children as young as two years old. read more By Arlene Weintraub Michigan State University researchers discovered that glial cells actively modify electrical signals in the gut to maintain normal functions like motility. They believe the findings could inspire new treatments for common conditions like inflammatory bowel disease and other motility disorders. read more By Paige Minemyer Humana is launching 72 new Medicare Advantage plans for 2022 across hundreds of additional counties, the insurer announced Friday. read more By Andrea Park The brain stimulation system includes a small device implanted on the patient’s brain that continuously monitors neurological activity and instructs two leads in separate areas of the brain to emit pulses if abnormal activity is detected. read more By Kyle LaHucik Anatara Lifesciences is joining the decentralized clinical trials movement. The Australian company will test a microbiome-targeted medicine for patients who have irritable bowel syndrome with diarrhea using in-home data through a partnership with ObvioHealth. read more By Natalie Missakian Rare disease patients, like many, are seeing pharma companies in a better light these days, but there’s still a need for transparency, fairer pricing and more patient engagement, according to a survey of 230 rare disease patient advocacy groups. read more |
|
